Overview information

Corporate philosophy With passion and exceptional technologies, experts in CMC research support the creation of outstanding and innovative drugs.SPERA PHARMA was established as a spin-out of Takeda Pharmaceutical Company by Chemistry, Manufacturing and Controls (CMC) research experts, who were already responsible for delivering numerous new drugs to high global acclaim. As a member of the Bushu Pharmaceuticals Group, SPERA PHARMA is responsible for the entire CMC process, from R&D through application; it provides services that meet the needs of customers. As the development of new drugs becomes increasingly difficult, SPERA PHARMA will hone technologies it has fostered and refined, advancing the research and development of promising drugs, and helping to achieve an even healthier society through the creation of outstanding new drugs.
Business Started July 1st, 2017
Capital 310 million yen
Representative Toshio Yoshioka, President
Address 17-85 Jusohonmachi 2-chome, Yodogawa-ku, Osaka 532-0024, Japan
Business Pharmaceuticals Contract R&D and Manufacturing
Directors and Officers Directors:Jun Yokohama, Toshio Yoshioka, Tetsuya Morikawa, Hidenori Tamura
Auditor:Yasuhiko Fujiu
Corporate Adviser:Katsuhiko Hatazawa


Access to head office

From JR Osaka Station

Walk from JR Osaka station to Hankyu Umeda station, and take a Hankyu train from Umeda station to Juso station. About 5-minute walk from Juso Station

From Shin-Osaka Station

Walk from Shin-Osaka Station to Nishinakajima-Minamikata Station of Osaka subway-Midosuji Line, and take a train to Hankyu Minamikata Station. Transfer to Hankyu-line to Hankyu Juso station. About 5-minute walk from Juso Station

From Osaka International Airport

Take an Osaka-monorail from Osaka International Airport to Hotarugaike Station, and transfer to Hankyu line to Hankyu Juso Station. About 5-minute walk from Juso Station


September, 2018


SPERA provides CMC solutions from early-stage through new drug application